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Abstract
HIV-1 infects lymphoid and myeloid cells, which can harbor a latent
proviral reservoir responsible for maintaining lifelong infection.
Glycolytic metabolism has been identified as a determinant of
susceptibility to HIV-1 infection, but its role in the development and
maintenance of HIV-1 latency has not been elucidated. By combining
transcriptomic, proteomic, and metabolomic analyses, we here
show that transition to latent HIV-1 infection downregulates glycol-
ysis, while viral reactivation by conventional stimuli reverts this
effect. Decreased glycolytic output in latently infected cells is associ-
ated with downregulation of NAD+/NADH. Consequently, infected
cells rely on the parallel pentose phosphate pathway and its main
product, NADPH, fueling antioxidant pathways maintaining HIV-1
latency. Of note, blocking NADPH downstream effectors, thioredoxin
and glutathione, favors HIV-1 reactivation from latency in lymphoid
and myeloid cellular models. This provides a “shock and kill effect”
decreasing proviral DNA in cells from people living with HIV/AIDS.
Overall, our data show that downmodulation of glycolysis is a meta-
bolic signature of HIV-1 latency that can be exploited to target
latently infected cells with eradication strategies.
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Introduction
Decades after its outbreak, the HIV/AIDS pandemic remains one of
the main causes of morbidity and mortality of humankind, leading
to almost one million victims per year (source: UNAIDS). Moreover,
due to the severe medical and economic crisis caused by coron-
avirus disease 2019 (COVID-19), adherence to and availability of
antiretroviral therapies (ART) are decreasing in areas where HIV/
AIDS prevalence is particularly high (Jewell et al, 2020; Jiang et al,
2020). This worsening of the death toll highlights the fragility of
current therapeutic approaches, based on lifelong ART administra-
tion. Therefore, a cure for HIV/AIDS is an unmet medical need of
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growing importance for people living with HIV/AIDS (PLWH). The
quest for a cure is hampered by persistence of transcriptionally
silent proviruses within latently infected cells, which render these
cells hard to discriminate from their uninfected counterparts (Finzi
et al, 1999). Latent HIV-1 DNA can be mainly found in viral reser-
voirs such as CD4+ T cells (Van Lint et al, 2013); however, myeloid
cells (in particular microglia) can also contribute to persistence of
the infection during ART (Sattentau & Stevenson, 2016). Pinpointing
molecular features to allow selective targeting of latently HIV-1-
infected cells would represent a significant, and perhaps decisive,
step in the quest for an HIV/AIDS cure.
A possible approach to reach this goal is the investigation of the
metabolic pathways exploited by the retrovirus to actively replicate
and enter a latent state. Several metabolic pathways have so far
been explored in the quest of a cure for HIV/AIDS. In the context of
a retroviral infection (characterized by a DNA proviral phase), one
of the first metabolic pathways to be explored was nucleotide meta-
bolism (Declercq E. New acquisitions in the development of anti-
HIV agents, 1989), in turn linked to several other metabolic path-
ways, including oxidative stress (Seifert et al, 1989; De Clercq,
2011), one of the most investigated but not yet fully understood
pathways. In particular, inhibition of oxidative stress has been
examined, starting from last century’s Nineties (Garaci et al, 1997),
as a strategy to induce a so-called “block and lock” effect, sending
the provirus to a deep latency state that is not reactivated when
ART is interrupted (Singh et al, 2021). Conversely, the activation of
oxidative stress has been explored in the context of the so-called
“shock and kill” strategies, aimed at purging the proviral reservoirs
by inducing HIV-1 escape from latency and their consequent elimi-
nation by cytopathogenicity or by the immune system (Yang et al,
2019). Profoundly linked to oxidative stress, iron metabolism has
been shown to lead, through its manipulation, to the selective death
of infected cells (Savarino et al, 1999; Hanauske-Abel et al, 2013;
Shytaj et al, 2020), but its clinical applications have so far been
hampered by off-target effects. Other pathways that might have ther-
apeutic potential in the setting of HIV-1 infection are autophagy
(Loucif et al, 2021) and the intertwined tryptophan/kynurenine (re-
viewed in: Routy et al, 2015) and nicotinamide metabolism
(Savarino et al, 1997; Lebouche et al, 2020). The importance of
understanding the relationship between cell metabolism and the
infection is emphasized by a recent case of long-term control of
HIV-1 without ART (Oral Abstracts from the 23rd International AIDS
Conference, 2020). This individual had been treated with a combi-
nation of intensified ART and nicotinamide, although the anecdotal
character of this case is suggested by lack of success in other similar
clinical attempts (Lebouche et al, 2020). Cells infected with HIV-1
display decreased levels of NAD+, an important substrate of glyco-
lytic reactions (Murray et al, 1995), and supplementation of the
NAD+ precursor nicotinamide influences viability of productively
HIV-1-infected cells (Savarino et al, 1996).
In this regard, it is interesting to point out that the cells more
susceptible to HIV-1 infection are characterized by an increased
glycolytic rate (Valle-Casuso et al, 2019). Increased glycolysis is
linked to cellular activation, which is necessary for active HIV-1
replication; of note, in CD4+ T cells and monocytes of HIV-1-
infected individuals, glucose consumption is increased and the
expression of the glucose transporter GLUT-1 is upregulated (Palmer
et al, 2014a, 2014b). Conversely, reports on the effect of HIV-1
infection on glycolysis have been sparse and, in some respects, con-
flicting. After ART implementation, PLWH showed to be more
susceptible to hyperglycemia than the general population (Dube
et al, 1997). On the other hand, upregulated glucose metabolism
was reported to favor apoptosis of infected CD4+ T cells (Hegedus
et al, 2014). Although these combined sets of data strongly support
a role of active glycolysis in determining susceptibility to HIV-1
infection as well as an altered glucose metabolism in PLWH, the role
of glycolysis in viral latency, and therefore in possible curing strate-
gies, has as yet remained unclear.
Indirect evidence of an interplay between glycolysis and HIV-1
latency can also be drawn by the dysregulation of redox pathways,
which are intertwined with glycolytic metabolism in several cell
types and pathological conditions (Kondoh et al, 2007; Locasale &
Cantley, 2011). This interconnection might be relevant, as we
recently showed that HIV-1 infection leads to enhancement of
antioxidant defenses in primary CD4+ T cells (Shytaj et al, 2020).
HIV-1 infection causes an initial oxidative stress (Daussy et al,
2020), which then leads to the nuclear translocation of the master
antioxidant transcription factor Nrf2. This translocation in turn
induces transcription of several proteins involved in antioxidant
response, including glucose-6-phosphate dehydrogenase (G6PDH),
which diverts glucose-6-phosphate from the glycolytic pathway to
the pentose cycle, responsible for the production of the antioxidant
NADPH. Therefore, elucidating the specific glycolysis/redox state
interconnection during HIV-1 infection would be of pivotal impor-
tance for understanding the molecular events which lead infected
cells to either die or establish a latent infection.
Herein, we combine transcriptomic, proteomic, and metabolomic
data sets, including single-cell analyses, to show that, during transi-
tion to HIV-1 latency, glycolysis is downregulated. In line with this,
our results show that latently infected cells able to undergo HIV-1
reactivation are more responsive to glycolysis reactivation. More-
over, we show that downregulation of glycolysis in latently infected
cells is accompanied by higher reliance on the antioxidant thiore-
doxin (Trx) and glutathione (GSH) systems for cell survival. Our
results highlight the possibility to exploit glycolytic imbalances
induced by HIV-1 infection for the elimination of retrovirally
infected cells. This result may improve our knowledge of pathways
that can be targeted by strategies aimed at eradicating HIV/AIDS.
Results
CD4+ T cells progressively downregulate the expression of
glycolytic enzymes in response to HIV-1 infection
To study transcriptomic profiles upon infection, we used microarray
and RNA-Seq data sets generated in primary CD4+ T cells infected
with HIV-1pNL4-3. The cellular model employed is based on longitu-
dinal sample collection to cover different time points, from early
HIV-1 infection [day 3 post-infection (p.i.)] to peak retroviral repli-
cation (days 7–9 p.i.) and latency/survival of infected cells (day 14
p.i.). The detailed features and validations of this cellular model
have been described previously elsewhere (Shytaj et al, 2020).
Microarray results, comprising a mean of late time points of
infection (days 7–14 p.i), highlighted significant downregulation of
the glycolytic pathway in infected cell cultures, which were
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independently evidenced by Gene Set Enrichment Analysis (GSEA;
Subramanian et al, 2005) either using a customized gene set
comprising enzymes involved in human glycolysis (henceforth,
HUMAN-GLYCOLYSIS) or using the Reactome or Biocarta databases
(Fig 1A; Appendix Table S1). Entrance of the infected cells into a
hypometabolic state was also shown by downregulation of
glycolysis-independent transcriptional and translational pathways,
although downregulation of these pathways did not reach the same
level of convergence among the databases examined as compared to
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enrichment plot: HUMAN-GLYCOLYSIS pathway
**** **** **** **** ******* **
C
Figure 1. Transcriptional modulation of glycolytic enzymes in productively or latently HIV-1-infected cells.
A–C Primary CD4+ T cells were activated with a-CD3-CD28 beads and infected with HIV-1pNL4-3 or mock-infected. Cells were cultured for 2weeks post-infection (p.i.) to
model different infection stages (days 3–9 p.i., i.e., productive infection; day 14 p.i., i.e., latent infection) and subjected to microarray (A, B; n = 2) or RNA-Seq (C; n =
3) analysis. (A) Gene set enrichment analysis (GSEA) of the expression of the glycolytic pathway (HUMAN-GLYCOLYSIS) in mock-infected or HIV-1-infected cells. (B,C)
Heatmaps of the relative expression of glycolytic enzymes upon HIV-1 infection. Data are expressed as Log2 fold change in HIV-1-infected vs mock-infected cells.
For microarray data (B), expression values of infected and mock-infected cells at different time points were pooled. For RNA-Seq data (C), expression values in
infected cells were normalized using the corresponding time point in mock-infected cells. Adjusted P-values (q values) to account for multiple testing were
calculated by Significance Analysis of Microarrays [SAM (Tusher et al, 2001)] and Deseq2 for RNA-Seq data (Love et al, 2014).
D–F scRNA-Seq of the expression of the entire glycolytic pathway or of glucose phosphate isomerase only (GPI) in primary CD4+ T cells infected in vitro (D,E) or CD4+
T cells of PLWH (F). In panels (D, E), cells were infected with VSVG-HIV-1-GFP and sorted for viral expression as detailed in Golumbeanu et al (2018). Following
latency establishment, cells were left untreated or HIV-1 expression was reactivated through suberoylanilide hydroxamic acid (SAHA) or a-CD3-CD28 engagement.
Clusters 1 and 2 were identified by principal component analysis as described in Golumbeanu et al (2018). In panel (F), CD4+ T cells were isolated from total blood
of PLWH under ART as described in Cohn et al (2018). Viral expression was reactivated by treatment with phytohemagglutinin (PHA), and cells were sorted using
antibodies against Env and Gag. Sorted cells were then subjected to scRNA-Seq analysis. The expression level of the HUMAN-GLYCOLYSIS pathway in (D) was
calculated as the average expression of genes comprising the gene list; expression levels in clusters 1 and 2 were compared using Wilcoxon rank-sum test. For
panels (E, F), significance of GPI differential expression level between clusters (E) or between control and Env+ Gag+ conditions (F) was assessed by the Wilcoxon
rank-sum test encoded in FindMarkers Seurat R function. **P < 0.01, ***P < 0.001; ***P < 0.0001. For panels (D, E) n = 1 donor, 43 cells (untreated), 90 cells (SAHA),
91 cells (TCR), for panel (F) n = 3 donors, 109 cells (control) and 85 cells (Gag+ Env+).
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pathways more heavily perturbed by HIV-1 infection, there was the
interferon pathway (Appendix Table S1), as expected, and pathways
associated with both apoptosis and cell cycle, in line with the fact
that, in an HIV-1-infected cell culture, some cells succumb to infec-
tion and others survive developing a proviral latent state.
We then analyzed in detail the glycolytic enzymes of the path-
way HUMAN-GLYCOLYSIS (Fig 1B). The glycolytic enzymes charac-
terized by significantly downregulated transcription upon infection
were hexokinase 2 (HK2), glucose-6-phosphate isomerase (GPI),
phosphofructokinase liver type (PFKL), aldolase fructose-
bisphosphate C (ALDOC), triosephosphate isomerase 1 (TPI1), and
enolase 2 (ENO2), thus suggesting a broad downregulation of the
glycolytic pathway (Fig 1B). In particular, the highly significant
downregulation of GPI suggests a glycolysis-specific effect, as this
enzyme commits metabolites to the glycolytic, rather than to the
alternative pentose phosphate pathway.
To expand these analyses, we explored an RNA-Seq data set
derived from the same primary CD4+ T-cell model, which was previ-
ously published elsewhere (Shytaj et al, 2020). In this data set, the
number of donors and time points was higher, allowing the study of
the expression of glycolytic enzymes during each infection stage
(Fig 1C). In line with the microarray results, differential gene expres-
sion analysis of RNA-Seq data (DESeq2) (Love et al, 2014) high-
lighted significant downregulation of glycolysis in infected cell
cultures, which were initiated during the late stages of HIV-1 repli-
cation (7–9 days p.i.) and persisted after retroviral replication had
ceased (14 days p.i.) (Fig 1D). In line with our microarray analysis,
enzyme transcriptional downregulation covered the main steps of
glycolysis, and the RNA-Seq data set further suggested that various
isoforms, in particular of PFK, might contribute differently to glycol-
ysis downregulation during productive or latent infection [PFK-
platelet (P); adjusted P-value= 0.04 at 7 days p.i. PFK-muscle (M);
adjusted P-value= 0.04 at 14 days p.i., respectively]. Finally, analy-
sis of a previously published proteomic data set of the same CD4+ T-
cell model (Shytaj et al, 2020) further corroborated the downregulat-
ing effect of HIV-1 on glycolysis, confirming significant downmodu-
lation of GPI, PGK1, and TPI1 (Appendix Fig S1).
Overall, these data show that HIV-1 infection, during its transi-
tion to latency, is associated with downregulated expression of
glycolytic genes.
Expression of glycolytic enzymes is required for HIV-1 escape
from latency in lymphoid and myeloid cells
The aforementioned results prove that glycolysis downregulation is
initiated during productive infection and accompanies HIV-1 latency
establishment. We then proceeded to specifically investigate the
transcriptional regulation of the HUMAN-GLYCOLYSIS pathway
upon the reverse process, i.e., reactivation from latency.
To this aim, we first analyzed two single-cell RNA-Seq (scRNA-
Seq) data sets independently published by the groups of Ciuffi and
Nussenzweig, respectively (Cohn et al, 2018; Golumbeanu et al,
2018). In the first data set, primary CD4+ T cells infected with pseu-
dotyped HIV-1-GFP/VSVG had been sorted according to GFP expres-
sion and allowed to revert to latency (Golumbeanu et al, 2018).
Latently infected cells had then been either left untreated or
subjected to HIV-1 reactivation by strong (a-CD3/CD28 antibodies)
or weak stimuli [suberoylanilide hydroxamic acid (SAHA)].
Eventually, the transcriptomic profile was analyzed by scRNA-Seq
(Golumbeanu et al, 2018). Using principal component analysis, the
authors identified two cell clusters, which were less (cluster 1) or
more (cluster 2) susceptible to HIV-1 reactivation (Golumbeanu
et al, 2018). We analyzed the expression of the enzymes of the
glycolytic pathway in both clusters and found that glycolytic
enzymes were downregulated in cells of cluster 1 (Fig 1D). Interest-
ingly, this relative downregulation, already visible in basal condi-
tions, was maintained upon treatment with either anti-CD3/CD28
antibodies or SAHA (Fig 1D). Moreover, GPI expression was lower
in the cell subpopulation less responsive to HIV-1 reactivation as
compared to the more susceptible cell subpopulation (Fig 1E), in
line with the results obtained on our model of latency establishment
(Fig 1B and C). Of note, also when CD4+ T-cell subsets were
analyzed separately to account for potential differences in their
metabolism (Loucif et al, 2020), cluster 1 was characterized by
downregulation of glycolysis in each detectable subset, corroborat-
ing lowered glycolysis as a general marker of latent HIV-1 infection
(Fig EV1).
To further validate the clinical relevance of these findings, we
analyzed a second scRNA-Seq data set obtained from CD4+ T cells
of PLWH under ART. To generate this data set, the Nussenzweig
group separated cells responsive to HIV-1 reactivation by detecting
Gag/Env expression upon treatment with the pan-lymphocyte acti-
vator, phytohemagglutinin (PHA) (Cohn et al, 2018). Despite its
limitations (the lower number of infected cells as compared to the
previously mentioned model and the likely presence of a mixed
population of infected and uninfected cells), this data set had the
advantage of capturing a viral reservoir generated under the patho-
physiologic conditions occurring in vivo in a clinical setting. In line
with the results shown by scRNA-Seq of in vitro infected cells, the
cell population responsive to HIV-1 reactivation displayed signifi-
cant upregulation of GPI (Fig 1F).
We then expanded our analysis to include microglial cells trans-
formed with SV40 and latently infected with HIV-1 [i.e., HC69 cells
(Alvarez-Carbonell et al, 2017; Garcia-Mesa et al, 2017)]. Microglia
constitutes one main myeloid retroviral reservoir during ART and is
largely responsible for HIV-1 persistence in the central nervous
system (Churchill & Nath, 2013). Our bulk RNA-Seq HC69 data,
along with data on its uninfected equivalent (C20 cells), allowed a
comparison of reactivated vs. latent infection through stimulation of
latently infected cells with tumor necrosis factor [TNF (Garcia-Mesa
et al, 2017)]. When infected cells were compared to their uninfected
counterparts incubated under similar conditions, results showed a
clear pattern of GPI downregulation being more significant in latent
than in productive infection and accompanied by a more
pronounced downregulation of the early glycolytic enzymes in the
former (Appendix Fig S2). Finally, scRNA-Seq profiling of HC69
cells highlighted a significantly positive correlation between base-
line HIV-1 expression and key glycolytic enzymes, including GPI, in
the subset of cells in which proviral transcription was detectable
(Fig EV2A and B). Conversely, treatment with dexamethasone
(DEXA), which is a known glycolysis inhibitor (Ma et al, 2013),
decreased both the proportion of HC69 cells expressing the tran-
scripts of the glycolytic pathway and the baseline percentage of cells
expressing HIV-1 transcripts (Fig EV2C).
Taken together, these results show that low expression of early
glycolytic enzymes, in particular GPI, is associated with HIV-1
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latency maintenance in multiple cellular models and subtypes and
that at least partial restoration of glycolysis is required for latency
disruption.
Decreased initial glycolytic metabolism during latent
HIV-1 infection
To evaluate changes in the metabolic profiles of cells characterized
by productive and latent HIV-1 infection, we subjected lymphoid
(Jurkat T cells) and myeloid (HC69 microglia) cell models to LC-
MS/MS metabolomic profiling (Figs 2 and EV3). These cell types
offer the advantage of providing data from a homogeneously
infected population. Four conditions were analyzed: quiescent, acti-
vated, latently infected, and productively infected.
Metabolite enrichment analysis showed significant changes in
the glycolysis/gluconeogenesis pathway in both latently and
productively infected cells, with glycolysis being one of the top scor-
ing pathways in both cell types analyzed (Figs 2A and B, and EV3A
and B).
When compared to uninfected cells in terms of single metabo-
lites, latently infected cells showed significantly decreased levels of
the initial glycolytic metabolite, i.e., glucose-6-phosphate, as well as
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Figure 2. Modulation of glycolysis and other metabolic pathways during productive or latent HIV-1 infection.
Latently HIV-1-infected (2D10) or uninfected (E6) Jurkat T cells were subjected to metabolomic analysis under unstimulated conditions or following stimulation with TNF
to reactivate latent HIV-1.
A, B Metabolite enrichment analysis in latently infected cells as compared to their uninfected counterparts (A) and cells reactivated from latency and compared with
latently infected cells (B). The top enriched pathways were ordered according to P-values obtained by Q statistics for metabolic data sets performed with Globaltest
(MetaboAnalyst) (Xia et al, 2009).
C Heatmaps of glycolytic metabolites in latently infected Jurkat T cells as compared to their uninfected counterparts or Jurkat T cells with HIV-1 reactivated by TNF
as compared to latently infected cells. Data are displayed as Log2 fold change expression. Adjusted P-values (q values) were calculated by the Benjamini–Hochberg
false discovery rate.
D, E Relative ratios of NADH/NAD+ (D) and ATP/ADP (E) in latently infected and reactivated cells. Data were normalized using the matching uninfected control.
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of the metabolite produced by PFK, i.e., fructose 1,6 bisphosphate
(Figs 2C and EV3C). Since the PFK enzyme acts immediately down-
stream of GPI, downregulation of fructose 1,6 bisphosphate appears
to be a consequence of the reduced expression of GPI in latently
infected cells (as shown by both RNA-Seq and scRNA-Seq analyses:
Fig 1C, E and F, Appendix Fig S2). When cells with reactivated HIV-
1 were compared to latently infected cells, a specular result was
obtained, with a relative increase in early glycolytic products (Figs
2C and EV3C), in line with the evidence that HIV-1 reactivation
increases transcription of the glycolytic enzyme GPI (Figs 1E and F,
and EV2B). The NADH/NAD+ ratio was decreased in latent infec-
tion, in both lymphoid and myeloid cells (Figs 2D and EV3D). More-
over, the ATP/ADP ratio was also decreased in latently infected
Jurkat T cells, but not in HC69 microglial cells (Figs 2E and EV3E),
suggesting an alternative source of ATP, other than glycolysis,
depending on the cell type examined. The late glycolytic metabo-
lites, such as lactate, also showed variable trends during infection
depending on the cell type analyzed (Figs 3 and EV4, Appendix Fig
S3), suggesting that the downregulation of early glycolytic steps is a
unifying metabolic signature of latency.
The variable regulation of late glycolytic metabolites can be
explained by their supply from alternative and partially overlapping,
or intertwined pathways. One such pathway is the pentose phos-
phate cycle, which can supply the glycolytic intermediate glycer-
aldehyde 3-phosphate through pentose conversion (Figs 3 and EV4).
The activity of the pentose phosphate cycle in latently infected cells
is shown by the increase in the pathway-specific metabolite sedo-
heptulose 7-phosphate (Figs 3 and EV4). However, NADPH levels in
latently infected cells were altered depending on a general depres-
sion of nicotinamide metabolism (Figs 2A, 3 and EV4) and on the
level of oxidized glutathione, which is generated by HIV-1 infection
(Shytaj et al, 2020) and reduced by NADPH consumption (Benhar
et al, 2016) (Figs 3 and EV4). Associated with the increased activity
of the pentose phosphate pathway is the upregulated pyrimidine
metabolism in latently infected cells (Figs 2A, 3 and EV4).
Apart from the pentose phosphate pathway, there was evidence
of a general metabolic attenuation in latently infected cells, with an
impaired lipidic catabolism in lymphoid and myeloid cells, respec-
tively (Figs 2A, 3, EV3A and EV4). This was also in line with an
increased number of lipid droplets in HIV-1-infected cells, although
their density remained unchanged (Appendix Fig S4).
Finally, the Krebs cycle, which is the energy production pathway
subsequent to glycolysis and lipid metabolism, also appeared to be
less active in latently infected cells, as shown by the decrease in its
main supply, i.e., acetyl-CoA (Fig 3). However, in latently infected
myeloid cells (Fig EV4), the Krebs cycle was in part maintained by
an alternative supply from glutamate metabolism (Figs EV3A and
EV4), as previously shown by Castellano et al (2019) and Gupta
et al (2010).
Overall, these results show that latently HIV-1-infected lymphoid
and myeloid cells are characterized by downregulation of early
glycolytic metabolites and by a compensatory activity of the parallel
pentose phosphate pathway. These changes are less pronounced in
productively infected cells, thus supporting their involvement in
HIV-1 latency.
HIV-1 transcription is a specific driver of metabolic changes
We then tested the hypothesis that HIV-1 expression may be a direct
cause of metabolic alterations. To isolate the metabolic effects of the
transcriptional status of HIV-1, we focused on the role of the lentivi-
ral transactivator Tat protein, which is required for the expression
of the integrated provirus through binding to the trans-activation
response (TAR) region, but can also activate numerous cellular
genes and molecular networks, especially those involved in
inflammatory responses (Clark et al, 2017).
First, we examined the effect of exogenous Tat administration
(i.e., known to lead to intracellular uptake of the fully active
protein) (Albini et al, 1995; Perkins et al, 2008) using the U1 cell
line, which displays a defective Tat/TAR axis (Emiliani et al, 1998).
The choice of Tat was also due to the fact that this protein has a
well-documented activity as oxidative stress inducer (Toborek et al,
2003; El-Amine et al, 2018) and oxidized glutathione was recog-
nized as a main NADPH consumer in our metabolomic analysis (Fig
). Tat administration was associated with increased expression of
HIV-1 (Appendix Fig S5A), as expected, as well as with upregulation
of the glucose transporter 1 (Glut1) in infected—but not in unin-
fected—cells (Appendix Fig S5B and C), in line with the upregula-
tion of glycolytic enzymes that we observed upon HIV-1
reactivation from latency (Fig 1). Administration of Tat also primed
infected cells for nucleotide (pyrimidine) synthesis, as shown by the
significant increase in carbamoyl-phosphate synthetase 2 (CAD)
expression (Appendix Fig S5B). This increase was visible in both
infected and uninfected cells (Appendix Fig S5B and C). These
changes are in line with an initial upregulation of cellular metabo-
lism necessary for HIV-1 replication, as reported by others (Valle-
Casuso et al, 2019). On the other hand, glutamine fructose 6-
phosphate transaminase (GFPT1), an enzyme starting a pathway
▸Figure 3. Schematic depiction of glycolysis and related metabolic networks in latently HIV-1-infected Jurkat T cells.The regulation of metabolic pathways was reconstructed based on the metabolomic data of latently infected Jurkat T cells (2D10) as compared to their uninfected
counterpart (E6). Enzymes are shown in italics. The figure includes the main energetic pathways described in the paper, as well as relevant connections with pathways
that were significantly enriched in the analysis shown in Fig 2A (gray boxes). The red arrows indicate the proposed path of the glucose carbon chains in latently infected
cells. Solid lines indicate direct connections. Dashed lines indicate indirect connections involving intermediate metabolites not shown in the figure. Networks were built
using the Cytoscape software (http://www.cytoscape.org) and the MetScape plugin (http://metscape.ncibi.org/tryplugin.html) (Gao et al, 2010) and adapted using Adobe
Illustrator (v 16.03). ACLY = ATP citrate lyase; ACO = aconitase; ADPGK = ADP-dependent glucokinase; ALDO = fructose 1,6 bisphosphate aldolase; ENO1 = enolase 1; FBP1 =
fructose-bisphosphatase; PFK = phosphofructokinase 1; FH = fumarate hydratase; H6PD = hexose-6-phosphate dehydrogenase; HK1 = hexokinase 1; G6PD = glucose-6-
phosphate dehydrogenase; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; GCK = glucokinase; GPDH = glycerol 3-phosphate dehydrogenase; GPI = glucose-6-
phosphate isomerase; KORA = ketoglutarate dehydrogenase A; IDH = isocitrate dehydrogenase; LDHAL6A = lactate dehydrogenase A like 6A; MDH1 =malate
dehydrogenase 1; PCK1 phosphoenolpyruvate carboxykinase 1; PFK = phosphofructokinase; PGAM4 = phosphoglycerate mutase family member 4; PGD = 6-
phosphogluconate dehydrogenase; PGK1 = phosphoglycerate kinase 1; PGLS = 6-phosphogluconolactonase; PGM1 = phosphoglucomutase 1; PKLR = pyruvate kinase L/R;
PRPS1 = ribose phosphate pyrophosphokinase 1; RPIA = ribose 5-phosphate isomerase; SDHA = succinate dehydrogenase complex flavoprotein subunit A; SUCD =
succinate semialdehyde dehydrogenase; TKT = transketolase; TPI = triose phosphate isomerase.
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bridging the pyrimidine and glutamine metabolism (Yelamanchi
et al, 2016), was not modulated by the presence of Tat
(Appendix Fig S5B and C).
Among other pathways affected by HIV-1 infection, there was a
trend toward an increase in G6PD, which is a rate-limiting enzyme
of the pentose phosphate pathway (Appendix Fig S5B and C).
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As G6PD was previously shown to be upregulated in HIV-1-
infected primary CD4+ T cells, during the late stages of the infection
(Shytaj et al, 2020), we decided to further test the role of proviral
transcription on the expression of G6PD in a longer time course of
infection with a wild type and a previously described Tat-deficient
HIV-1 (Bejarano et al, 2019). The results showed that infection with
Tat-deficient HIV-1 led to lower retroviral transcription (Fig 4A), as
expected, and, in contrast to the wild-type HIV-1, was not associated
with increased expression of G6PD (Fig 4B). Thus, Tat is required to
induce the upregulation of this enzyme during the productive infec-
tion stage, and, subsequently, high enzyme levels are then main-
tained upon latency establishment (Shytaj et al, 2020). Of note, this
result is in line with the role of the pentose phosphate cycle in fuel-
ing pyrimidine synthesis through ribose 5-phosphate (Fig EV4). In
line with previous evidence showing that G6PD expression is
accompanied by an antioxidant response (Shytaj et al, 2020) and
with the pro-oxidant activity of Tat (El-Amine et al, 2018), the Tat
mutant HIV-1 also failed to induce two main antioxidant genes
acting downstream of NADPH production by the pentose phosphate
cycle (Louboutin & Strayer, 2014) (Fig 4C and D). In particular, Tat
was necessary to induce the expression of thioredoxin reductase 1
(TrxR1) (Fig 4C) and glutamate-cysteine ligase (GCLC) (Fig 4D),
which are essential for the function of the thioredoxin (Trx) and
glutathione (GSH) pathways, acting downstream of NADPH produc-
tion.
Downstream inhibition of the glycolysis-alternative pentose
phosphate pathway can induce a “shock and kill” effect in
latently infected cells
We then tested whether blocking the downstream, NADPH-
mediated antioxidant effects of the pentose phosphate cycle could
induce HIV-1 escape from latency and reduce the ability of infected
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Figure 4. Relative expression of HIV-1 gag and genes regulating the pentose phosphate pathway or antioxidant responses in CD4+ T cells infected with wild
type and Tat-deficient HIV-1.
Primary CD4+ T cells were isolated from total blood of healthy donors and activated with a-CD3-CD28 beads for 72 h. Cells were then mock-infected or infected with
wild-type HIV-1pNL4-3 or with Tat-deficient HIV-1pNL4-3 (Bejarano et al, 2019). Cells were cultured for 1week post-infection, and gene expression was measured by qPCR.
A Relative expression of HIV-1 gag in cells infected with Tat-deficient HIV-1pNL4-3 as compared to cells infected with wild-type HIV-1 pNL4-3.
B–D Relative expression of the limiting rate enzyme of the pentose phosphate pathway, i.e., G6PD (B), and of genes regulating the thioredoxin and glutathione
antioxidant pathways, i.e., TrxR1 (C) and GCLC (D), in HIV-1 infected as compared to mock-infected cells.
Data information: Data were first normalized using 18S as housekeeping control and then expressed as Log2 fold mRNA expression in wild type vs Tat-deficient
infection (panel A) or in infected vs mock-infected cells (panels B-D), which were calculated using the 2-DDCT method (Livak & Schmittgen, 2001). GCLC =
glutamate—cysteine ligase; TrxR1= thioredoxin reductase 1. Data are expressed as mean SD of two replicates and were analyzed by two-way ANOVA followed
by Sidak’s post-test. *P < 0.05.
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For this purpose, we chose the drugs auranofin (AF) and
buthionine sulfoximine (BSO), which, by inhibiting Trx and GSH
regeneration, respectively (Benhar et al, 2016), can block the
antioxidant/pro-latency effect of NADPH. These drugs were also
preferred because of their translational potential, due to their clini-
cal (separately) and pre-clinical (combined) testing as anti-reservoir
compounds in PLWH and macaques infected with the simian
immunodeficiency virus (SIV) (Benhar et al, 2016; Diaz et al, 2019).
As expected, at the concentrations chosen for the reactivation exper-
iments, the two drugs were able to synergistically increase oxidative
stress in a previously described reporter model which allows
measuring GSH potential in live cells (Bhaskar et al, 2015)
(Appendix Fig S6). When we analyzed HIV-1 production in a
number of proviral latency models, we found that AF/BSO favored
proviral reactivation, at different efficiencies, in both lymphoid and
myeloid models (Fig EV5A).
Moreover, when cell viability was analyzed, results showed that
combined inhibition of Trx and GSH led to the preferential killing of
HIV-1-infected cells as compared to their uninfected counterparts
(Fig EV5B), although specific leukemia/lymphoma cell lines were
highly sensitive to AF and BSO treatment irrespective of HIV-1 infec-
tion, in line with the previously described sensitivity of such neopla-
sias to these drugs (Fiskus et al, 2014; Benhar et al, 2016).
To increase the translational relevance of our findings, we tested
the combination of AF and BSO in primary-like/primary lymphoid
cells (Fig 5), choosing Th17 cells and cells isolated from total blood
of PLWH to model, respectively, tissue (Hunt, 2010) and peripheral
reservoirs. In line with our results on other cellular models,
combined AF/BSO treatment was able to induce HIV-1 reactivation
and preferential death of infected Th17 cells (Fig 5A and B). As for
cells from PLWH, we initially conducted an analysis of the meta-
bolic profiles of peripheral blood mononuclear cells (PBMCs), show-
ing significant enrichment of the pentose cycle upon treatment with
both AF and BSO as compared to cells treated with BSO only
(Appendix Fig S7). These effects were not detectable when cells
treated with AF-only were compared with cells treated with BSO,
thus supporting a specific impact of the drug combination on the
pentose cycle. These results are also in line with the well-known
compensation of GSH inhibition by the Trx system (Benhar et al,
2016), thus confirming that only the combination of both drugs can
lead to a sustained pro-oxidant effect. When we tested the therapeu-
tic potential of AF and BSO on CD4+ T cells of PLWH with stably
suppressed viremia under ART (Appendix Table S2), it was not
possible to separately analyze the viability of the latently infected
cells, because of the low frequency of these cells in peripheral
blood. We thus chose to measure the effect of the treatment on the
selective elimination of HIV-1-infected cells. For this purpose, CD4+
T cells were left untreated or treated for 48 h with AF, BSO, or a
combination of the two, and cells were then sorted for viability
(Appendix Fig S8A) to eliminate the potential bias of the general
cytotoxic effect of AF on lymphocytes (Chirullo et al, 2013)
(Appendix Fig S8B). The frequency of the total integrated proviral
DNA was then measured by Alu-PCR, and normalization of the
proviral DNA copies to the number of cells examined allowed to
standardize the analysis. The results showed that proviral HIV-1
DNA was significantly lower in the cell cultures that had received
both AF and BSO (Fig 5C). Of note, cells from two of the donors
showed loss of integrated proviral DNA signal after AF/BSO treat-
ment. In line with the hypothesis of an increased mortality of HIV-1
infected cells carrying intact proviruses, AF and BSO exerted only
minor effects on early products of HIV-1 reactivation as measured
by Tat/rev Induced Limiting Dilution Assay [TILDA (Procopio et al,
2015)], which is based on proviral expression in intact cells
(Appendix Fig S9). Interestingly, the specificity of the result of
proviral DNA decrease is further corroborated by the analysis of
general cell culture viability before sorting. Indeed, unlike proviral
DNA decrease, the decrease in general cell viability was mainly
affected by AF (Appendix S8B), as previously shown (Chirullo et al,
2013), and not specifically by the AF/BSO combination.
Overall, these data show that glycolysis downregulation and
increased reliance on the pentose cycle in latently HIV-1-infected
cells can be exploited by pro-oxidant drugs targeting Trx and GSH to
induce HIV-1 reactivation and/or mortality of infected cells.
Discussion
The present study highlights the central role of downregulation of
glycolytic activity as a determinant of the transition from productive
to latent HIV-1 infection, an effect that is reversed upon proviral
reactivation. By integrating our data with the extant literature, we
may now distinguish two phases characterizing the cellular inter-
play between glycolysis and HIV-1 infection.
In the first phase, HIV-1 preferentially replicates in fully activated
cells, a cellular milieu characterized by elevated glycolysis, that is
optimal to sustain high levels of viral replication. In line with an
initial enhancement of glycolysis upon HIV-1 infection described by
others (Valle-Casuso et al, 2019; Guo et al, 2021), our data show
that the HIV-1 transactivator Tat can mediate Glut1 upregulation,
thus favoring the intracellular import of glucose needed by glycoly-
sis, as a mechanism of maximal exploitation of the metabolic
machinery of the host cell by the retrovirus.
The second phase, accompanied by changes in host cell metabo-
lism and glycolytic regulation during establishment of proviral
▸Figure 5. “Shock and kill” effect of combined thioredoxin (Trx) and glutathione (GSH) inhibition in primary lymphoid models of HIV-1 infection.A, B Reactivation from HIV-1 latency (A) and relative cell viability (B) in primary Th17 cells following 24 h treatment with the Trx inhibitor auranofin (AF; 500 nM), the
GSH inhibitor buthionine sulfoximine (BSO; 250 lM), or a combination of the two. GFP-HIV-1 expression was determined by FACS. Data are expressed as mean SD
of three replicates and were analyzed by one-way ANOVA followed by Tukey’s post-test (A) or two-way ANOVA followed by Sidak´s post-test (B). Solid lines
represent the means.
C Levels of integrated HIV-1 DNA following treatment for 48 h with AF and/or BSO in CD4+ T cells derived from PLWH under suppressive antiretroviral therapy. Live
cells were sorted after treatment, and integrated DNA was measured by Alu-PCR. The latency reactivating agent SAHA was used as a reference compound (Archin
et al, 2012). Data were analyzed by non-parametric Friedman´s test followed by Dunn’s post-test.
Data information: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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latency, has not been previously characterized. We show that entry
into the latent phase of the infection is accompanied by a profound
metabolic rearrangement, with general depression of the energy-
producing pathways, in particular glycolysis, and reliance on other
energy sources (Fig 6). One such source is the pentose cycle, which
provides infected cells with antioxidants that are necessary for HIV-
1 latency induction (Shytaj et al, 2020). In this regard, we show
upregulation of the interconnected pyrimidine metabolism, which is
involved in reactive oxygen species (ROS) production (Tabata et al,
2018). The effects of pyrimidine metabolism might underlie G6PD
upregulation, which is observed during late-productive and latent
HIV-1 infection (Shytaj et al, 2020). Of note, G6PD can in turn
decrease the levels of glucose-6-phosphate, thus potentially explain-
ing downmodulation, by substrate subtraction, of the early
glycolytic enzyme GPI (Dyson & Noltmann, 1968). While our data
indicate that some of the metabolic changes are a direct effect of
HIV-1, our results are not incompatible with a role of lentivirus-
independent factors, such as the reversal to cellular quiescence, that
may drive the cell to both glycolysis downregulation and establish-
ment of HIV-1 latency.
The importance of downregulated glycolysis for latency mainte-
nance is further shown by the effect of latency-reversing stimuli,
which we show to partially restore glycolytic activity. Again, this
may be due to specific retroviral factors such as HIV-1 Tat, but also
be an epiphenomenon of general cellular activation. In this regard,
single-cell analysis shows that the inability to upregulate glycolysis
is associated with impaired viral reactivation, potentially suggesting
a link between cellular metabolism and deep latency.
Figure 6. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress.
Schematic model of the regulation of glycolysis during sequential stages of HIV-1 infection and of its potential therapeutic targeting (created with BioRender).
Uninfected cells become susceptible to HIV-1 infection upon activation by upregulating a number of metabolic pathways including glycolysis (Valle-Casuso et al, 2019).
During productive HIV-1 infection, glycolysis is progressively downregulated, a process which is in part compensated by reliance on the parallel pentose phosphate
pathway. Latent HIV-1 infection can ensue either spontaneously, leading to further glycolysis downregulation, or be induced by agents such as dexamethasone (DEXA),
which can directly inhibit glycolysis. During latency, the pentose phosphate pathway remains active and fuels, through NADPH activity, regeneration of the two main
antioxidant molecules, i.e., Trx and GSH. Reversion to a productively infected state is accompanied by partial reactivation of the glycolytic pathway. Blocking Trx and GSH
inhibits downstream effects of NADPH without restoring glycolytic activity, thus favoring death of latently infected cells. TrxR = thioredoxin reductase; GCLC = glutamate-
cysteine ligase; GSSG = oxidized GSH.
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Our analysis of the glycolytic pathway at a single-cell resolution
helps to reconcile our results with the works of Palmer et al, which
showed that glycolysis is upregulated in PLWH, independently of
ART (Palmer et al, 2014a, 2014b). PLWH are characterized by
chronic immune hyperactivation (Deeks et al, 2004), also when
viral loads are stably suppressed by ART. As the percentage of
latently infected cells in vivo is low, it is conceivable that their lower
glycolytic activity is masked in vivo by hyperactivated cells and their
bystander effects. Another result apparently contradictory to ours
was obtained by Castellano et al (2019), who analyzed a time
course of macrophages infected in vitro with HIV-1 and concluded
that glycolysis might not be impaired in latently infected macro-
phages. However, their conclusions were based on the analysis of
the acidification capability (a byproduct of late glycolysis), while
our results, instead, highlight the downmodulation of the early
phases of glycolysis in latently infected cells. Indeed, our data are
consistent with those of Castellano et al in showing that lactate, the
main metabolite responsible for extracellular acidification, as well
as its precursor, pyruvate, may even be increased in some latently
infected cell types due to the simultaneous activation of other path-
ways, bypassing the early glycolytic pathway.
Although we focused primarily on glucose metabolism, we were
also able to evaluate a number of alternative energy-producing path-
ways that are modulated in latently infected cells. While a full
reconstruction of other pathways will require stepwise analysis in
future works, our metabolomic analysis suggests that the Krebs
cycle (Wu et al, 2015; Vi~na et al, 2016), which intervenes down-
stream of glycolysis, is another biochemical pathway possibly
affected by HIV-1 latency. In lymphoid cells, acetyl-CoA, and citrate,
the initial metabolites of the Krebs cycle are decreased. In agreement
with Castellano et al (2019), our report confirms that, in latently
infected myeloid cells, glutamate becomes a readily alternative
source for the Krebs cycle. Interestingly, another source for the
Krebs cycle supply, lipid degradation, which exerts a positive role in
PLWH by favoring anti-HIV-1 immune responses (Loucif et al,
2021), is inactive in late cellular HIV-1 infection.
Although inhibition of glycolysis might become an interesting
tool to prevent proviral reservoir establishment (Valle-Casuso et al,
2019), this inhibitory approach does not provide a viable strategy
for targeting the viral reservoirs, once they are established. For
example, the glycolysis inhibitor 2-DG was able to decrease viral
replication and kill the infected cells in newly infected cultures
where glycolytic metabolism remained high. On the other hand,
data derived from the clinic have shown that enhancers, rather than
inhibitors, of glycolysis may be beneficial to PLWH (Planas et al,
2021).
Another hallmark of HIV-1 infection identified by our metabo-
lomic analysis is an altered metabolism of nicotinamide, which is
required for the synthesis of NADP+, the precursor of the antioxi-
dant NADPH, which is the main pentose cycle product. Therefore,
limited availability of the NADP+/NADPH machinery may contri-
bute to the increased sensitivity of infected cells to inhibitors of the
downstream effects of the pentose phosphate cycle. In particular,
NADPH acts as a cofactor for the regeneration of the two most
important antioxidant defenses, Trx and GSH (Benhar et al, 2016;
Miller et al, 2018), implying that dual inhibition of the Trx and GSH
pathways might induce a vicious cycle (Fig 6). In this regard, an
interesting parallel can be drawn with neoplastic cells, as previous
studies showed increased susceptibility to the cytotoxic effects of
combined Trx and GSH pathway inhibition in lung cancer cells with
pharmacologically inhibited glycolysis (Fath et al, 2011; Li et al,
2015).
Of particular importance, the drugs used in the present work (AF
and BSO) had already shown the potential to decrease the viral
reservoir in macaques and PLWH (Shytaj et al, 2015; Diaz et al,
2019). A similar effect was observed in macaques treated with
another pro-oxidant compound and Trx pathway inhibitor, i.e.,
arsenic trioxide (Yang et al, 2019). One characteristic of these strate-
gies was not only the elimination of latently infected cells in vivo
but also the enhancement of anti-HIV-1 cell-mediated immunity
(Shytaj et al, 2015). In light of the results of the present study, this
immune enhancement could be interpreted as a consequence of the
“shock” effect against viral latency provided by the combined inhi-
bition of the Trx and GSH pathways. One limitation of the current
approach is, however, the lack of complete specificity toward HIV-1-
infected cells. Future studies will be required to identify more selec-
tive compound combinations or to determine the hormetic dose
zone of AF and BSO which be capable of exerting the maximal
effects in infected cells, while sparing uninfected cells. Although still
controversial for some agents, the concept of a U-shaped dose
response due to counteracting responses is becoming widely
accepted in redox biology (Zimmermann et al, 2014). However, the
present study was bound to well-established drug concentrations
able to significantly inhibit their targets.
Taken together, our results highlight glycolysis downregulation
as a distinctive metabolic feature of latently HIV-1-infected cells
which can potentially be exploited to block entry of viruses into
latency or subsequently target latent reservoirs.
Materials and Methods
Cell cultures and HIV-1 infection
The following cell lines or primary cells were used as models of
productive or latent HIV-1 infection: (i) lymphoid cells: (a) latently
HIV-1-infected J-Lat 9.2 cells and uninfected Jurkat T cells, (b)
latently HIV-1-infected primary Th17 cells (Alvarez-Carbonell et al,
2017), (c) primary CD4+ T cells from healthy donors infected with
HIV-1 in vitro (Shytaj et al, 2020), and (d) primary CD4+ T cells from
PLWH with viral loads stably suppressed by ART; (ii) myeloid cells:
(a) the THP-1 monocytic cell line, (b) the U937 and U1 (latently
HIV-1 infected) promonocytic cell lines, (c) primary human
monocyte-derived macrophages (Shytaj et al, 2013), (d) human
immortalized microglia (hµglia) clone C20 (uninfected) and clone
HC69 (latently infected with HIV-1) (Alvarez-Carbonell et al, 2017;
Garcia-Mesa et al, 2017; Llewellyn et al, 2018), and (e) iPSC-derived
microglia (iMG) uninfected or infected with HIV-1 (iMG/HIV)
(Alvarez-Carbonell et al, 2019); and (iii) reporter TZM-bl cells trans-
fected with HIV-1 Gag-mCherry viruses pseudotyped with JR-FL Env
or without Env.
Lymphoid cells
The parental Jurkat E6.1 (ATCC number: TIB-152) cell line and the
latently HIV-1-infected J-Lat 9.2 cell line (Jordan, 2003) were
cultured using RPMI+10% fetal bovine serum (FBS) and plated at
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0.25–0.5 × 106 cells/ml as previously described (Shytaj et al, 2020).
Latently infected 2D10 Jurkat T cells were cultured as described in
Alvarez-Carbonell et al (2017).
Latently HIV-1-infected Th17 cells were generated as previously
described (Garcia-Mesa et al, 2017; Dobrowolski et al, 2019). Briefly,
naive CD4+ T cells were isolated using a RoboSep CD4+ Na€ıve T-cell
negative selection kit (STEMCELL Technologies Inc., Vancouver,
British Columbia, Canada), and 2 × 106 cells were resuspended in 10
ml RPMI medium and stimulated with 10 µg/ml concanavalin A
(ConA) (EMD Millipore, Billerica, MA, USA) in the presence of
subset-specific cytokines. Cells were cultured for 72 h at 37°C,
followed by addition of 10ml of fresh medium, additional 10 µg/ml
ConA, polarization cocktail cytokines, and 120 IU/ml of IL-2. After 6
days, cells were washed and resuspended in RPMI medium supple-
mented with the growth cytokines IL-23 (50 ng/ml) and IL-2 (60 IU/
ml). Cells were then infected in a 24-well plate using VSV
glycoprotein-pseudotyped virus expressing CD8 and GFP at a multi-
plicity of infection (MOI) of 2 at a cellular concentration of 5 × 106 cells
per ml, in the presence of cell subset cytokines. Cells were spinocu-
lated at 2,000 × g for 1.5 h at room temperature and then placed in an
incubator overnight. Cells were adjusted to 1 × 106 per ml in the pres-
ence of cell subset-appropriate growth cytokines. After 48 h, infection
efficiency was determined by GFP expression and infected cells were
isolated using RoboSep mouse CD8a-positive selection kit II (STEM-
CELL Technologies Inc., Vancouver, British Columbia, Canada). Cells
(50 × 106 per ml) were pre-incubated with 50 µl/ml of antibody cock-
tail from the kit and 40 µl/ml of magnetic beads and diluted into 2.5
ml RoboSep buffer. Positive cells were recovered by magnetic bead
separation, suspended in 1ml of medium, and vortexed to release the
cells and beads from the tube wall.
Primary CD4+ T cells for in vitro HIV-1 infection were isolated
from total blood of healthy individuals using the RosetteSepTM Human
CD4+ T Cell Enrichment Cocktail (STEMCELL Technologies Inc.,
Vancouver, British Columbia, Canada) as previously described (Shy-
taj et al, 2020) and according to the manufacturer’s instructions. The
blood was obtained through the Heidelberg University Hospital Blood
Bank following approval by the local ethics committee. To induce
activation before HIV-1 infection Dynabeads Human T-Activator
CD3/CD28 was added to cells for 72 h. Cells were then mock-infected
or infected using 2 ng p24 of HIV-1pNL4-3/10
6 cells. Mock-infected and
HIV-1 infected cells were then cultured for 2 weeks in RPMI+20%
FBS with 10 ng/ml IL-2 at a density of 0.5–2 × 106/ml. At 3, 7, 9, and
14 days post-infection, 1 × 106 cells were pelleted and used for RNA
extraction and transcriptomic analysis (microarray and RNA-Seq) as
previously described (Shytaj et al, 2020).
For ex-vivo experiments on CD4+ T cells or PBMCs of PLWH,
cells from adult donors were analyzed. Experiments were conducted
in conformity to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report. The use of samples was approved by the Institu-
tional Review Board of the Centre Hospitalier Universitaire Vaudois
and by the Human Subjects Review Committee of the Federal
University of Sao Paulo. All subjects gave written informed consent.
Experiments were exclusively performed on cells isolated from
treated PLWH with undetectable viremia (HIV-1 RNA levels < 50
copies per ml of plasma) for at least 12 months. Culture conditions
and HIV-1 reactivation experiments were conducted as described in
Procopio et al (2015).
Myeloid cells
For producing latently HIV-1-infected THP-1 (ATCC number: TIB-
202) cell cultures, uninfected cells were cultured on a 6-well plate at
a density of 1 × 106 cells per well in RPMI growth medium contain-
ing 10% FBS, 1% penicillin/streptomycin, and 50 nM of 2-
mercaptoethanol. Infection with a HIV-1-GFP virus was carried out
by spinoculation, as described in Alvarez-Carbonell et al (2017).
Positively selected cells were placed in RPMI medium with cell type-
specific growth cytokines at 1 × 106 in upright flasks and allowed to
expand for a week prior to treatments. During all assays, suspension
cells were cultured at a density of 1 × 106 cells per ml, in 96-well
plates in a volume of 100 µl.
Monocytic cell lines U937 and U1 (harboring the latent HIV-1
provirus) were cultured in RPMI+10% FBS. Cells were stably
transduced to express the Grx1-roGFP2 biosensors in cytoplasm as
described previously (Bhaskar et al, 2015).
The procedure used to generate hµglia/HIV HC69 from C20 was
previously described in Garcia-Mesa et al (2017). Cells were
cultured in BrainPhysTM medium (STEMCELL Technologies Inc.,
Vancouver, British Columbia, Canada) containing 1× N2
supplement-A (Gibco, Invitrogen, #17502–048), 1× penicillin–strep-
tomycin (GibcoTM, #15140122), 100 lg/ml NormocinTM (InvivoGen,
#ant-nr-1), 25mM glutamine (Gibco TM, #25030081), 1% FBS, and 1
lM DEXA (freshly added to the cell culture) (Sigma-Aldrich,
#D4902), as previously described (Garcia-Mesa et al, 2017). For
experiments, cells were plated at 0.1 × 106 cells per well in 24-well
plates.
Human iPSC-derived microglia (Tempo-iMGTM; Tempo
Bioscience, CA) was cultured in DMEM/F-12 (Thermo Fisher,
Waltham, MA, USA) supplemented with 1× N2 supplement, 0.5×
NEAA, 2mM L-Glutamine, 100 ng/ml GM-CSF, 50 ng/ml IL-34, and
infected with VSVG-HIV-GFP as previously described (Alvarez-
Carbonell et al, 2019). The experiments with iMG and iMG/HIV
cells (adherent) were performed 72 h post-infection at a density of
50,000 cells per well in a 96-well plate pre-coated with Growth
Factor Reduced Matrigel (Corning Inc., Corning, NY, USA).
TZM-bl cells
TZM-bl (kindly provided by Dr. Quentin Sattentau, University of
Oxford) and Lenti-XTM 293T cells (Takara Bio, Clontech, Saint
Germain en Laye, France) were cultured in either complete DMEM
or complete DMEM F-12 (Thermo Fisher, Waltham, MA, USA),
respectively, supplemented with 10% FBS and 1% penicillin–strep-
tomycin. Cells were grown at 37°C in the presence of 5% CO2.
For HIV-1 pseudovirus production, the pR8DEnv plasmid (encod-
ing HIV-1 genome harboring a deletion within env), pcRev, and
NL4-3 Gag-mCherry DEnv were kindly provided by Dr. Greg
Melikyan (Emory University, Atlanta, GA, USA). The plasmid
encoding JR-FL Env was a kind gift from Dr James Binley (Torrey
Pines Institute for Molecular Studies, FL, USA). For lactate measure-
ments, Laconic construct was obtained from Addgene (ref. 44238).
HIV-1 pseudovirus bearing Gag-mCherry was produced as
described previously (Coomer et al, 2020). Briefly, Lenti-XTM 293T
cells were transfected at 60–70% confluency with a mix of
pR8DEnv, pcRev, NL4-3 Gag-mCherry DEnv and with or without JR-
FL Env, at a 2:1:3:3 ratio, using GeneJuice transfection reagent
(Novagen, EMD Millipore, Billerica, MA, USA). 72 h after transfec-
tion, viral supernatants were collected, filtered (0.45 lm), and
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concentrated using Lenti-XTM Concentrator (Takara Bio, Clontech,
Saint Germain en Laye, France).
Tzm-bl cells were plated onto 8-well µ-Slide (Cat. No: 81826,
Ibidi, Gr€afelfing, Germany) and transfected on the same day with
250 ng of plasmid expressing the Laconic biosensor per well, using
GeneJuice transfection reagent. 12 h post-transfection, the medium
was replaced with fresh complete DMEM after washing with PBS 1×
and cells were incubated for further 4 h at 37°C. 16 h post-
transfection, cells were infected at MOI of 1 with HIV-1 Gag-
mCherry viruses pseudotyped with JR-FL Env or without Env as a
negative control for infection (No Env viruses). Viruses were diluted
in a final volume of 100 ll FluoroBrite DMEM 2% FBS (Thermo
Fisher, Waltham, MA, USA) per well and added onto cells. Cells
were spinoculated at 2,100 g in a refrigerated centrifuge (4°C) for 20
min. The viral inoculum was then removed, and cells were washed
with PBS 1× and incubated for further 90min in FluoroBrite DMEM
2% FBS at 37°C to allow viral fusion to occur. The medium was
later replaced by complete DMEM, and cells were again incubated
at 37°C. Transfected cells expressing Laconic, challenged to HIV-1
pseudoviruses, were analyzed by Fluorescence Lifetime Microscopy
(FLIM) 3 days post-infection as described below.
RNA extraction
Total cellular RNA was extracted using the InviTrap Spin Univer-
sal RNA Mini Kit (Stratec Biomedical, Germany) according to the
manufacturers’ instructions and as previously described (Shytaj
et al, 2020). RNA concentration was assessed using a P-class P 300
NanoPhotometer (Implen GmbH, Munich, Germany).
Microarray and RNA-Seq analyses
Primary CD4+ T cells infected with HIV-1 or mock-infected were
subjected to microarray and RNA-Seq using 500 ng of total RNA that
was quality checked for integrity via Bioanalyzer. Microarray was
performed using the HumanHT-12 beadchip (Illumina, Inc., 5200
Illumina Way San Diego, CA 92122 USA) and scanned using an
iScan array scanner. Data extraction was done for all beads individ-
ually, and outliers were removed when the absolute difference to
the median was > 2.5 times MAD (2.5 Hampelıs method). Raw data
are available at GSE163405.
Bead-level microarray raw data were converted to expression
values using the lumi R package for quality control, variance stabi-
lization, normalization, and gene annotation (Du et al, 2008).
Briefly, raw data and control probes were loaded in R using the
lumiR and addControlData2lumi functions. Raw signals were back-
ground corrected, estimating the background based on the control
probe information with the bgAdjust method of the lumiB function.
Background corrected data were then processed with the variance-
stabilizing transformation (VST) of the lumiT function to stabilize
the variance and were finally normalized using the quantile normal-
ization implemented in lumiN. Gene expression data were anno-
tated using the R package illuminaHumanv4.db that contains the
mappings between Illumina identifiers and gene descriptions.
To identify the impact of HIV-1 infection on gene expression, we
compared the expression levels of CD4+ T cells infected with HIV-1
with those of mock-infected cells using Significance Analysis of
Microarray (Tusher et al, 2001) algorithm coded in the same R
package. In SAM, we estimated the percentage of false-positive
predictions (i.e., false discovery rate, FDR) with 100 permutations
and selected as differentially expressed those genes with an FDR
q-value ≤ 0.05.
Over-representation analysis was performed using Gene Set
Enrichment Analysis (Subramanian et al, 2005) and using the gene
sets of the Biocarta and Reactome collections from the Broad Insti-
tute Molecular Signatures Database (http://software.broadinstitute.
org/gsea/msigdb) as well as a customized gene set derived from
AmiGO (see section “Glycolysis pathway” below). GSEA software
(http://www.broadinstitute.org/gsea/index.jsp) was applied on
Log2 expression data of cells infected with HIV-1 or matched mock-
infected controls. Gene sets were considered significantly enriched
at FDR < 5% when using Signal2Noise as a metric and 1,000 permu-
tations of gene sets.
Differential expression of genes in RNA-Seq data sets was
analyzed using the DESeq2 package (Love et al, 2014). The data sets
used were retrieved from Shytaj et al (2020) (GSE127468) for CD4+
T cells and from Garcia-Mesa et al (2017) (SRP075430) for unin-
fected (C20) and HIV-1-infected (HC69) microglia. Heatmaps were
generated using the Morpheus tool (https://software.broadinstitute.
org/morpheus).
ScRNA-Seq analyses
scRNA-Seq data sets were retrieved from Golumbeanu et al (2018)
(GSE111727) and from Cohn et al (2018) (GSE104490) and analyzed
with the Seurat [version 3.1.5; (Stuart et al, 2019)] R package. In
particular, normalized gene expression data for GSE111727 were
downloaded from Zenodo repository (Zenodo_Data_S2) and loaded
into a Seurat object; raw gene counts for GSE104490 were down-
loaded from GEO and normalized using Seurat. T-cell subsets were
classified using the SingleR R package (Aran et al, 2019). Differen-
tially expressed genes were calculated using the FindMarkers func-
tion of the Seurat package.
The scRNA-Seq data of HC69 (GSE163979) were generated as
follows: Immortalized human microglia HC69 cells were left
untreated or treated with dexamethasone [DEXA, 1 lM (Sigma-
Aldrich, St. Louis, MO, USA)] for 72 h. After harvesting, a minimum
of 600,000 viable cells per condition was subjected to Drop-Seq as
described in Macosko et al (2015). After capturing individual cells
in the oil droplets with barcoded beads (ChemGenes, Inc. Wilming-
ton, MA, 01887 USA), droplets were broken, and cDNA libraries
were generated using Illumina Nextera XT kit (Illumina, Inc., 5200
Illumina Way San Diego, CA, 92122 USA). Next-generation sequenc-
ing and quality control were performed at MedGenome Inc (Foster
City, CA, 94404 USA). Drop-Seq Tools v.1.0 and STAR-2.5.1b align-
ment tools were used to process and map the sequences to the hg18
human reference genome and to the retroviral portion of the HIV-
1pNL4-3 construct. As a result, we built digital gene expression matri-
ces (DGE) containing the read counts for human and HIV-1 genes.
The DGE matrices were used to generate the Seurat objects. After fil-
tering, a total of 6,528 control and 5,869 DEXA-treated individual
cell transcriptome profiles were consolidated, each expressing at
least 100 genes, with each gene expressed in at least 3 cells. To
prevent “zero inflation” bias, further filtering was performed to
isolate only cells expressing HIV-1 and the genes of the glycolytic
pathway (HUMAN-GLYCOLYSIS). Correlation scatter plots were
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built using Seurat, accompanied by the calculations of the Spearman
correlation coefficients R and related P-values.
Proteomic analysis
Proteomic analysis of CD4+ T cells infected in vitro with HIV-1 or
mock-infected was retrieved from Shytaj et al (2020). The data set is
available at the ProteomeXchange Consortium via the PRIDE (Perez-
Riverol et al, 2019) partner repository with the data set identifier
PXD012907. Relative protein quantificationwas performed by Despite
Data-independent Acquisition (DIA) processing raw data with Spec-
tronaut Pulsar X (version 11) using default and previously described
parameters (Shytaj et al, 2020). Heatmaps were generated using the
Morpheus tool (https://software.broadinstitute.org/morpheus).
Metabolomic analysis
Metabolomic analysis was performed as described previously (Li
et al, 2020). Briefly, polar metabolites were extracted from cells
using a cold extraction solution containing 80% methanol and 20%
water. Samples were analyzed by LC-MS/MS on a Thermo Q Exac-
tive HF-X mass spectrometer coupled to a Vanquish LC System. LC
separation was performed by hydrophilic interaction liquid chro-
matography (HILIC), pH 9, using a SeQuant ZIC-pHILIC column
(MilliporeSigma). Peak areas, representing metabolite levels, were
extracted using Thermo Compound Discoverer 3.0. The following
data normalization procedures were used for each data set depend-
ing on the available parameters: (i) Data derived from microglia
cells (HC69 and C20) were normalized to protein amount; (ii) data
derived from Jurkat cells (2D10 and E6) were normalized to total
intensity of the identified metabolites; and (iii) data derived from
PBMCs of PLWH were normalized to equivalent cells injected on
column. Metabolites were identified by accurate mass and retention
based on pure standards and by accurate mass and MS/MS fragmen-
tation followed by searching the mzCloud database (www.mzcloud.
org). For heatmap generation, Log2 fold change values were calcu-
lated based on average expression values from triplicate samples.
Statistically significant changes were assessed by Student’s t-test (P-
value) and the Benjamini–Hochberg false discovery rate (FDR) to
account for multiple testing (q-value).
Metabolite pathway and enrichment analysis were performed
using MetaboAnalyst 4.0 (http://www.metaboanalyst.ca) (Xia et al,
2009). For enrichment analysis, a table of raw peak intensity values
was submitted to the platform and the Benjamini–Hochberg FDR
correction was used to adjust all P-values and reduce false-positive
discovery for multiple testing. The q conversion algorithm was then
used to calculate FDRs in multiple comparisons using FDR < 0.05 as
threshold for significance in all tests.
For pathway analysis, Human Metabolome Database (HMBD)
(Wishart, 2020) IDs of the metabolites differentially expressed
between the conditions compared were submitted to the MetaboAn-
alyst platform. Comparisons were analyzed by Student’s t-test using
Holm’s correction for multiple comparisons, so as to generate a q-
value. The library ’Homo sapiens (human)’ of the Human Metabo-
lome Database was used for pathway analysis. For network genera-
tion, metabolite data were integrated with the RNA-Seq data of the
same microglia model (described in its dedicated methods section).
As input data, KEGG IDs, P-values, and Log2 fold changes were used
for the selected compounds (metabolites and gene transcripts). In
order to analyze a correlation network of the compounds in shared
pathways, MetScape (Gao et al, 2010), an app implemented in Java
and integrated with Cytoscape (version 3.5.1), was used.
Glycolysis pathway
Except for a priori analysis (GSEA and metabolic pathway enrich-
ment), the list of enzymes and metabolites used to define the glyco-
lytic pathway was selected based on known literature and to reflect
all metabolic/enzymatic steps associated with glycolysis irrespective
of the cell type examined. Specifically, the gene list was retrieved
from AmiGO Gene ontology using the filters: GO:0061621 (canonical
glycolysis) AND Homo sapiens (pathway named in the paper as:
HUMAN-GLYCOLYSIS). The metabolite list was retrieved from the
KEGG Pathway database entry M00001 [Glycolysis (Embden-
Meyerhof pathway)].
Drug treatments
For glycolysis inhibition, TZM-bl cells infected with JR-FL without
Env (No Env virus) were treated with 100mM 2-deoxy-glucose
(2-DG) (Sigma-Aldrich, St. Louis, MO, USA) 2 h prior to image
acquisition.
For viral reactivation and cell viability experiments, cells were
treated with auranofin (Sigma-Aldrich #A6733; 500 nM), L-
Buthionine-sulfoximine (i.e., Sigma-Aldrich BSO #B2515; 250 lM),
or a combination of the two for 24 or 48 h as indicated in the
captions of Additional files 8, 9, and 11. In parallel, cells were incu-
bated with one of the following positive control activating agents/-
drugs: a-CD3/CD28 beads (1:1 bead-to-cell ratio), TNF (10 ng/ml),
12-O-tetradecanoylphorbol-13-acetate at 10 lM concentration (TPA;
Sigma-Aldrich, Saint Louis, MI, USA), and suberoylanilide hydrox-
amic acid 0.5 lM (SAHA; Selleckchem, Houston, TX, USA S1047).
Lipid droplets and HIV-1 p24 staining
TZM-bl cells exposed to HIV-1 Gag-mCherry viruses pseudotyped
with JR-FL Env (MOI 1) were fixed 3 dpi using 4% paraformaldehyde
(PFA). Fixed cells were blocked/permeabilized using 10% fetal
bovine serum (FBS), 0.5% saponin in PBS buffer (Immunofluores-
cence, IF, buffer). Primary antibodies recognizing HIV-1 p24
(ab53841, Abcam) were diluted in IF buffer to 4 µg/ml and applied to
cells for 1h in a humid chamber at 37°C. Anti-goat secondary antibod-
ies conjugated to Alexa 488 dye (A-11055, Invitrogen) were diluted to
2 µg/ml in IF buffer and added to cells for 30min at 37°C. Lipid
droplet staining was performed adding Nile Red dye (Cat 60029,
Biotium) diluted in PBS to 1 µg/ml, and the preparation was incu-
bated for 10min at room temperature. Excess of Nile Red dye was
removed by washing twice with PBS before microscopy imaging.
Fluorescence lifetime imaging microscopy (FLIM)
Fluorescence microscopy experiments on fixed TZM-bl cells
expressing HIV-1 p24 and stained with Nile Red dye were performed
using the PicoQuant MicroTime 200 confocal microscope. Cells were
imaged under a 60×/NA 1.20 water objective. HIV-1 p24 expressing
cells (immuno-stained with Alexa 488 and Nile Red dye) were
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excited using a 485-nm pulsed laser, tuned at 40MHz, and subse-
quently detected by a hybrid detector (500–550 nm) and a single-
photon avalanche diode (SPAD) detector (650–690 nm). Images
were acquired with a laser dwell time of 1.3 µs with a pixel size of
180 nm and obtained after 20 times frame repetitions.
Time-domain FLIM experiments on live TZM-bl cells expressing
Laconic were performed using a Time-correlated Single Photon
Counting (TCSPC) approach operated by the FALCON module
(Leica Microsystems, Manheim, Germany) integrated within the
Leica SP8-X-SMD microscope. Cells of interest were selected under a
63×/NA 1.20 water objective. Laconic-expressing cells were excited
using a 440-nm pulsed laser, tuned at 40MHz, and subsequently
detected by a hybrid internal detector (475–510 nm) in photon
counting mode. Transfected cells co-expressing Laconic and Gag-
mCherry were also excited using a DPSS 561 continuous laser, and
mCherry fluorescence emission was detected by a hybrid internal
detector (525–560 nm). Images were acquired using a scan speed
of 200 Hz with a pixel size of 120 nm and obtained after 10 times
frame repetitions.
Image analysis
Fluorescence intensity analysis of confocal microscopy images was
performed using ImageJ software. HIV-1-infected cells (p24-Alexa
488 positive) vs uninfected cells (p24-Alexa 488 negative) were iden-
tified in the 500–550 nm emission channel. Number of lipid droplets
per cell was quantified from the 650–690 nm emission channel using
the “Find maxima” tool in ImageJ. Results were statistically analyzed
performing an unpaired t-test (GraphPad Prism 9.1.0).
FLIM images were analyzed using the FALCON module (Leica
Microsystems, Manheim, Germany) integrated within the Leica SP8-
X-SMD microscope. Images were binned 3 × 3 to reach at least 100
counts/pixel. Individual cells expressing Laconic alone (No Env
infected) or co-expressing Gag-mCherry were selected as regions of
interest. A two-exponential decay deconvoluted with the Instrument
Response Function (IRF) and fitted by a Marquardt nonlinear least-
square algorithm was applied to the photon counting histogram
with the long lifetime component fixed to 2.6 ns. The average life-
time, intensity weighted (TauInt) was calculated per cell and
normalized to the mean TauInt of the no-Env condition of each
experiment. Normalized results from three independent experiments
were statistically analyzed using a one-way ANOVA test (OriginLab
software, Northampton, USA).
MTT assay of cell viability
Cell viability upon treatment with auranofin and/or BSO was
measured using the CellTiter 96Non-Radioactive Cell Proliferation
Assay (MTT) (Promega; Madison, WI, USA) according to the manu-
facturer’s instructions, as described in Shytaj et al (2020). Absor-
bance values were measured using an Infinite 200 PRO (Tecan,
M€annedorf, Switzerland) plate reader. After blank subtraction, absor-
bance values were normalized using matched untreated controls.
Flow cytometry and cell sorting
To measure GFP expression in J-Lat 9.2 cells, 500 × 105 cells were
fixed with 4% PFA in PBS, washed twice with PBS, and
resuspended in the FACS buffer. GFP fluorescence was measured
using a BD FACSCelesta (Becton Dickinson, Franklin Lakes, NJ,
USA) flow cytometer and analyzed using the FlowJo software
(FlowJo LLC, Ashland, Oregon, USA v7.6.5).
GFP expression in hµglia/HIV HC69 and HIV-1-infected iPSC-
derived microglia was measured using a LSRFortessa instrument for
cell sorting, the FACSDiva software (Becton Dickinson, Franklin
Lakes, NJ, USA) for data collection, and the WinList 3D software
(Verity Software House, Topsham, ME, USA) for data analysis.
Viability of U937 and U1 cells was assessed by propidium iodide
staining. Briefly, cells were suspended in PBS and stained with 1.5
µM propidium iodide (PI) for 15min in the dark. After washing
twice with PBS, cells were analyzed on a flow cytometer using the
phycoerythrin detector with 488 nm excitation and 575/26 nm emis-
sion on a FACSVerse Flow cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA).
The expression of CD4 in cells of PLWH was detected with an
anti-human-CD4 antibody conjugated to PE-CF594 (BD PharMingen
Catalog No. 562281). Cells were sorted based on viability using the
PE Annexin V Apoptosis Detection Kit I (BD PharMingen Catalog
No. 559763) using a LSR Aria cell sorter and the FACSDiva software
(Becton Dickinson, Franklin Lakes, NJ, USA) for data collection.
Redox potential measurement
Intracellular redox potential measurements in U1 cells were done as
described earlier (Bhaskar et al, 2015). Briefly, the ratio-metric
response of cells expressing the Grx1-roGFP2 sensor was obtained
by measuring excitation at 405 and 488 nm at a fixed emission
(510/10 nm) using a FACS Verse Flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA).
Real-time PCR and ALU-HIV PCR
The expression of HIV-1 (Gag-p24) in U1 cells and of metabolic
genes in U1 and U937 cells were measured by qPCR as described
previously (Bhaskar et al, 2015). Briefly, total cellular RNA was
reverse transcribed to cDNA (iScriptTM cDNA synthesis kit, Bio-
Rad, Hercules, CA, United States). Real-time PCR (iQTM SYBR
Green Supermix, Bio-Rad Hercules, CA, United States) was
performed using the Bio-Rad C1000TM real-time PCR system. The
primers for Gag-24 and housekeeper b-actin genes were described
elsewhere (Bhaskar et al, 2015). The following primers were used to
amplify metabolic genes: (i) GLUT1, forward CTGCTCATCAACCG
CAAC, reverse CTTCTTCTCCCGCATCATCT; (ii) G6PD, forward
CTGTTCCGTGAGGACCAGATCT, reverse TGAAGGTGAGGATAACG
CAGGC; (iii) CAD, forward GTTTGCAGTCCTTCCCGC, reverse
CCGGTTTGAAACACCACTTCC; and (iv) GFPT1, forward CCAGCCA
GTTTGTATCCCTT, reverse CAAGCATGATCTCTTTGCGT. Relative
fold change levels were calculated using the delta delta CT method.
All experiments were done at least twice in triplicate.
The expression of antioxidant genes in primary CD4+ T cells was
measured by qPCR using the conditions and primers described in
Shytaj et al (2020).
To measure integrated HIV-1 DNA in live CD4+ T cells of PLWH,
Alu-HIV PCR was performed as described in Chomont et al (2009).
HIV-1 reactivation in the same cell types was measured by Tat/rev
Induced Limiting Dilution Assay as described in Procopio et al (2015).
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Statistical analysis
Statistical analysis of in-silico data is described in the respective
Methods subchapters. HIV-1 reactivation and cell viability data were
analyzed by parametric (i.e., one- or two-way ANOVA tests) or non-
parametric (i.e., Friedman test). Parametric testing was adopted
when normality could be hypothesized (sample size ≤ 3) or restored
through an appropriate transformation. Data sets characterized by
sample size > 3 which did not pass the normality tests (D’Agostino
& Pearson or Shapiro–Wilk) and for which a transformation was not
applicable were analyzed by non-parametric tests. For both para-
metric and non-parametric tests, post-test comparisons were used to
compare specific groups as described in the Figure captions. Analy-
ses were performed using GraphPad Prism (GraphPad Software, San
Diego, CA, USA).
Data availability
The data sets produced in this study are available in the following
databases:
• Microarray: Gene Expression Omnibus GSE163405 (https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163405)
• RNA-Seq data: DDBJ Sequence Read Archive SRP075430 (https://
trace.ddbj.nig.ac.jp/DRASearch/study?acc=SRP075430)
• scRNA-Seq: Gene Expression Omnibus GSE163979 (https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi)
Expanded View for this article is available online.
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